Terms: = Pancreatic cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
34 results:
1. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic cancer Models.
Vuaroqueaux V; Musch A; Peille AL; Kelter G; Weichert L; Metz T; Hendriks HR; Fiebig HH
Cancer Res Commun; 2023 Oct; 3(10):2170-2181. PubMed ID: 37830744
[TBL] [Abstract] [Full Text] [Related]
2. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
3. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract] [Full Text] [Related]
4. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
5. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract] [Full Text] [Related]
6. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Adhikari H; Kattan WE; Kumar S; Zhou P; Hancock JF; Counter CM
Nat Commun; 2021 Sep; 12(1):5248. PubMed ID: 34504076
[TBL] [Abstract] [Full Text] [Related]
7. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract] [Full Text] [Related]
8. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
[TBL] [Abstract] [Full Text] [Related]
9. Ras sumoylation in cell signaling and transformation.
Dai W; Xie S; Chen C; Choi BH
Semin Cancer Biol; 2021 Nov; 76():301-309. PubMed ID: 33812985
[TBL] [Abstract] [Full Text] [Related]
10. First Long-term Oncologic Results of the ALPPS Procedure in a Large Cohort of Patients With Colorectal Liver Metastases.
Petrowsky H; Linecker M; Raptis DA; Kuemmerli C; Fritsch R; Kirimker OE; Balci D; Ratti F; Aldrighetti L; Voskanyan S; Tomassini F; Troisi RI; Bednarsch J; Lurje G; Fard-Aghaie MH; Reese T; Oldhafer KJ; Ghamarnejad O; Mehrabi A; Abraham MET; Truant S; Pruvot FR; Hoti E; Kambakamba P; Capobianco I; Nadalin S; Fernandes ESM; Kron P; Lodge P; Olthof PB; van Gulik T; Castro-Benitez C; Adam R; Machado MA; Teutsch M; Li J; Scherer MN; Schlitt HJ; Ardiles V; de Santibañes E; Brusadin R; Lopez-Lopez V; Robles-Campos R; Malagó M; Hernandez-Alejandro R; Clavien PA
Ann Surg; 2020 Nov; 272(5):793-800. PubMed ID: 32833765
[TBL] [Abstract] [Full Text] [Related]
11.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract] [Full Text] [Related]
12. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and nras Mutations in Cell-Free DNA.
Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
[TBL] [Abstract] [Full Text] [Related]
13. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Kinsey CG; Camolotto SA; Boespflug AM; Guillen KP; Foth M; Truong A; Schuman SS; Shea JE; Seipp MT; Yap JT; Burrell LD; Lum DH; Whisenant JR; Gilcrease GW; Cavalieri CC; Rehbein KM; Cutler SL; Affolter KE; Welm AL; Welm BE; Scaife CL; Snyder EL; McMahon M
Nat Med; 2019 Apr; 25(4):620-627. PubMed ID: 30833748
[TBL] [Abstract] [Full Text] [Related]
14. pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical cancer.
Hashimoto D; Arima K; Nakagawa S; Negoro Y; Hirata T; Hirota M; Inomata M; Fukuzawa K; Ohga T; Saeki H; Oki E; Yamashita YI; Chikamoto A; Baba H; Maehara Y
J Gastroenterol; 2019 May; 54(5):437-448. PubMed ID: 30515563
[TBL] [Abstract] [Full Text] [Related]
15. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability.
Adhikari H; Counter CM
Nat Commun; 2018 Sep; 9(1):3646. PubMed ID: 30194290
[TBL] [Abstract] [Full Text] [Related]
16. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical pancreatic cancer Models.
Jiang H; Xu M; Li L; Grierson P; Dodhiawala P; Highkin M; Zhang D; Li Q; Wang-Gillam A; Lim KH
Mol Cancer Ther; 2018 Oct; 17(10):2144-2155. PubMed ID: 30065098
[TBL] [Abstract] [Full Text] [Related]
17. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract] [Full Text] [Related]
18. Clinical Implications of nras Overexpression in Resectable pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract] [Full Text] [Related]
19. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract] [Full Text] [Related]
20. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype.
Hong TS; Wo JY; Borger DR; Yeap BY; McDonnell EI; Willers H; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Tanguturi S; Goyal L; Murphy JE; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Tanabe KK; Ferrone CR; Ryan DP; Iafrate AJ; DeLaney TF; Zhu AX
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954285
[TBL] [Abstract] [Full Text] [Related]
[Next]
